Literature DB >> 30488111

Histogram analysis of amide proton transfer-weighted imaging: comparison of glioblastoma and solitary brain metastasis in enhancing tumors and peritumoral regions.

Kiyohisa Kamimura1, Masanori Nakajo1, Tomohide Yoneyama1, Yoshihiko Fukukura1, Hirofumi Hirano2, Yuko Goto3, Masashi Sasaki4, Yuta Akamine5, Jochen Keupp6, Takashi Yoshiura7.   

Abstract

OBJECTIVES: Differentiation of glioblastomas (GBMs) and solitary brain metastases (SBMs) is an important clinical problem. The aim of this study was to determine whether amide proton transfer-weighted (APTW) imaging is useful for distinguishing GBMs from SBMs.
METHODS: We examined 31 patients with GBM and 17 with SBM. For each tumor, enhancing areas (EAs) and surrounding non-enhancing areas with T2-prolongation (peritumoral high signal intensity areas, PHAs) were manually segmented using fusion images of the post-contrast T1-weighted and T2-weighted images. The mean amide proton transfer signal intensities (APTSIs) were compared among the EAs, PHAs, and contralateral normal appearing white matter (NAWM) within each tumor type. Furthermore, we analyzed APTSI histograms to compare the EAs and PHAs of GBMs and SBMs.
RESULTS: In GBMs, the mean APTSI in EAs (2.92 ± 0.74%) was the highest, followed by that in PHAs (1.64 ± 0.83%, p < 0.001) and NAWM (0.43 ± 0.83%, p < 0.001). In SBMs, the mean APTSI in EAs (1.85 ± 0.99%) and PHAs (1.42 ± 0.45%) were significantly higher than that in NAWM (0.42 ± 0.30%, p < 0.001), whereas no significant difference was found between EAs and PHAs. The mean and 10th, 25th, 50th, 75th, and 90th percentiles for APT in EAs of GBMs were significantly higher than those of SBMs. However, no significant difference was found between GBMs and SBMs in any histogram parameters for PHA.
CONCLUSIONS: APTSI in EAs, but not PHAs, is useful for differentiation between GBMs and SBMs. KEY POINTS: • Amide proton transfer-weighted imaging and histogram analysis in the enhancing tumor can provide useful information for differentiation between glioblastomas and solitary brain metastasis. • Amide proton transfer signal intensity histogram parameters from peritumoral areas showed no significant difference between glioblastomas and solitary brain metastasis. • Vasogenic edema alone can substantially increase amide proton transfer signal intensity which may mimic tumor invasion.

Entities:  

Keywords:  Glioblastoma; Magnetic resonance imaging; Metastasis

Mesh:

Substances:

Year:  2018        PMID: 30488111     DOI: 10.1007/s00330-018-5832-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  28 in total

1.  Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI.

Authors:  Jinyuan Zhou; Jean-Francois Payen; David A Wilson; Richard J Traystman; Peter C M van Zijl
Journal:  Nat Med       Date:  2003-07-20       Impact factor: 53.440

2.  A pyramid approach to subpixel registration based on intensity.

Authors:  P Thévenaz; U E Ruttimann; M Unser
Journal:  IEEE Trans Image Process       Date:  1998       Impact factor: 10.856

3.  Amide proton transfer imaging of human brain tumors at 3T.

Authors:  Craig K Jones; Michael J Schlosser; Peter C M van Zijl; Martin G Pomper; Xavier Golay; Jinyuan Zhou
Journal:  Magn Reson Med       Date:  2006-09       Impact factor: 4.668

Review 4.  The extracellular space and matrix of gliomas.

Authors:  Josef Zamecnik
Journal:  Acta Neuropathol       Date:  2005-09-21       Impact factor: 17.088

5.  Single Brain Metastasis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2001-01       Impact factor: 3.598

6.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps.

Authors:  Kyrre E Emblem; Baard Nedregaard; Terje Nome; Paulina Due-Tonnessen; John K Hald; David Scheie; Olivera Casar Borota; Milada Cvancarova; Atle Bjornerud
Journal:  Radiology       Date:  2008-06       Impact factor: 11.105

8.  Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

Authors:  S Cha; J M Lupo; M-H Chen; K R Lamborn; M W McDermott; M S Berger; S J Nelson; W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2007 Jun-Jul       Impact factor: 3.825

9.  Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas.

Authors:  M Law; R Young; J Babb; E Pollack; G Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2007-04       Impact factor: 3.825

10.  Amide proton transfer (APT) contrast for imaging of brain tumors.

Authors:  Jinyuan Zhou; Bachchu Lal; David A Wilson; John Laterra; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2003-12       Impact factor: 4.668

View more
  8 in total

Review 1.  Neuroimaging at 7 Tesla: a pictorial narrative review.

Authors:  Tomohisa Okada; Koji Fujimoto; Yasutaka Fushimi; Thai Akasaka; Dinh H D Thuy; Atsushi Shima; Nobukatsu Sawamoto; Naoya Oishi; Zhilin Zhang; Takeshi Funaki; Yuji Nakamoto; Toshiya Murai; Susumu Miyamoto; Ryosuke Takahashi; Tadashi Isa
Journal:  Quant Imaging Med Surg       Date:  2022-06

2.  Differentiation of Meningiomas and Gliomas by Amide Proton Transfer Imaging: A Preliminary Study of Brain Tumour Infiltration.

Authors:  Han-Wen Zhang; Xiao-Lei Liu; Hong-Bo Zhang; Ying-Qi Li; Yu-Li Wang; Yu-Ning Feng; Kan Deng; Yi Lei; Biao Huang; Fan Lin
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

3.  Amide Proton Transfer Weighted Imaging Shows Differences in Multiple Sclerosis Lesions and White Matter Hyperintensities of Presumed Vascular Origin.

Authors:  Elisabeth Sartoretti; Thomas Sartoretti; Michael Wyss; Anton S Becker; Árpád Schwenk; Luuk van Smoorenburg; Arash Najafi; Christoph Binkert; Harriet C Thoeny; Jinyuan Zhou; Shanshan Jiang; Nicole Graf; David Czell; Sabine Sartoretti-Schefer; Carolin Reischauer
Journal:  Front Neurol       Date:  2019-12-10       Impact factor: 4.003

4.  Differentiation Between Glioblastoma Multiforme and Metastasis From the Lungs and Other Sites Using Combined Clinical/Routine MRI Radiomics.

Authors:  Yuqi Han; Lingling Zhang; Shuzi Niu; Shuguang Chen; Bo Yang; Hongyan Chen; Fei Zheng; Yuying Zang; Hongbo Zhang; Yu Xin; Xuzhu Chen
Journal:  Front Cell Dev Biol       Date:  2021-08-26

Review 5.  Molecular Imaging of Brain Tumors and Drug Delivery Using CEST MRI: Promises and Challenges.

Authors:  Jianpan Huang; Zilin Chen; Se-Weon Park; Joseph H C Lai; Kannie W Y Chan
Journal:  Pharmaceutics       Date:  2022-02-20       Impact factor: 6.321

6.  The Value of APTw CEST MRI in Routine Clinical Assessment of Human Brain Tumor Patients at 3T.

Authors:  Julia P Lingl; Arthur Wunderlich; Steffen Goerke; Daniel Paech; Mark E Ladd; Patrick Liebig; Andrej Pala; Soung Yung Kim; Michael Braun; Bernd L Schmitz; Meinrad Beer; Johannes Rosskopf
Journal:  Diagnostics (Basel)       Date:  2022-02-14

Review 7.  The Management of Brain Metastases-Systematic Review of Neurosurgical Aspects.

Authors:  Martin A Proescholdt; Petra Schödel; Christian Doenitz; Tobias Pukrop; Julius Höhne; Nils Ole Schmidt; Karl-Michael Schebesch
Journal:  Cancers (Basel)       Date:  2021-03-31       Impact factor: 6.639

8.  Physiological MRI Biomarkers in the Differentiation Between Glioblastomas and Solitary Brain Metastases.

Authors:  Elisabeth Heynold; Max Zimmermann; Nirjhar Hore; Michael Buchfelder; Arnd Doerfler; Andreas Stadlbauer; Natalia Kremenevski
Journal:  Mol Imaging Biol       Date:  2021-04-23       Impact factor: 3.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.